Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion–positive metastatic non–small cell lung cancer: a phase 1 …

C Zhou, SS Ramalingam, TM Kim, SW Kim… - JAMA …, 2021 - jamanetwork.com
Importance Metastatic non–small cell lung cancer (mNSCLC) withEGFRexon 20 insertion
(EGFRex20ins) mutations is associated with a poor prognosis. Mobocertinib is an oral …
被引用次数：240 相关文章

[引用][C] Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung …

C Zhou, SS Ramalingam, TM Kim, SW Kim, JCH Yang… - JAMA Oncology, 2021 - cir.nii.ac.jp
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With <i>EGFR</i>
Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer | CiNii Research CiNii …

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A …

C Zhou, SS Ramalingam, TM Kim, SW Kim… - JAMA …, 2021 - europepmc.org
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR
Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label …

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A …

김상위 - 2021 - oak.ulsan.ac.kr
Importance: Metastatic non-small cell lung cancer (mNSCLC) with EGFR exon 20 insertion
(EGFRex20ins) mutations is associated with a poor prognosis. Mobocertinib is an oral …
[HTML] nih.gov

[HTML][HTML] Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung …

C Zhou, SS Ramalingam, TM Kim, SW Kim… - JAMA …, 2021 - ncbi.nlm.nih.gov
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR
Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer - PMC Back to Top Skip to …

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients with EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A …

C Zhou, SS Ramalingam, TM Kim, SW Kim… - JAMA …, 2021 - snucm.elsevierpure.com
Importance: Metastatic non-small cell lung cancer (mNSCLC) with EGFR exon 20 insertion
(EGFRex20ins) mutations is associated with a poor prognosis. Mobocertinib is an oral …

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A …

C Zhou, SS Ramalingam, TM Kim, SW Kim… - JAMA …, 2021 - pubmed.ncbi.nlm.nih.gov
Importance Metastatic non-small cell lung cancer (mNSCLC) with EGFR exon 20 insertion
(EGFRex20ins) mutations is associated with a poor prognosis. Mobocertinib is an oral …

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A …

C Zhou, SS Ramalingam, TM Kim, SW Kim… - JAMA …, 2021 - europepmc.org
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR
Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer: A Phase 1/2 Open-label …